Group | Cases n | Baseline | Week 2 | Week 12 |
Nontreated | 14 | 0.19 (0.02–0.48) | 0.21 (0.08–0.55) | |
GC-treated | 51 | 0.23 (0.08–0.38) | 0.41 (0.20–0.90)** | 0.31 (0.09–0.52)# |
Without asthma | 18 | 0.23 (0.13–0.44) | 0.37 (0.08–1.12)* | 0.39 (0.21–0.65)* |
With asthma | 33 | 0.23 (0.07–0.37) | 0.47 (0.21–0.86)* | 0.26 (0.07–0.51)## |
ATA | 16 | 0.24 (0.11–0.34) | 0.55 (0.21–0.92) | 0.19 (0.07–0.51) |
AIA | 17 | 0.18 (0.05–0.60) | 0.40 (0.21–0.69) | 0.27 (0.04–0.52) |
Data are presented as median (interquartile range) ×106 cDNA copies·μg−1 total RNA, unless otherwise stated. ATA: aspirin-tolerant asthma; AIA: aspirin-intolerant asthma. *: p<0.05; **: p<0.01; both compared with baseline (Wilcoxon test). #: p<0.05; ##: p<0.01; both compared with week 2 (Wilcoxon test).